期刊
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
卷 22, 期 2, 页码 389-402出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beem.2008.01.016
关键词
5 alpha-reductase; 5 alpha-reductase inhibitor; androgen; Avodart; benign prostatic hyperplasia; dihydrotestosterone; dutasteride; finasteride; prostate; prostate cancer
Androgens play an essential role in prostatic development and function, but are also involved in prostate disease pathogenesis. The primary prostatic androgen, dihydrotestosterone (DHT), is synthesized from testosterone by 5 alpha-reductase types 1 and 2. Inhibition of the 5 alpha-reductase isoenzymes therefore has potential therapeutic benefit in prostate disease. The two currently approved 5 alpha-reductase inhibitors (5ARIs), finasteride and dutasteride, have demonstrated long-term efficacy and safety in the treatment of benign prostatic hyperplasia. Finasteride, a type-2 5ARI, has also been studied for its ability to reduce the incidence of biopsy-detectable prostate cancer in the Prostate Cancer Prevention Trial. Treatment with dutasteride, a dual 5ARI, has been shown to result in a greater degree and consistency of DHT suppression compared with finasteride. Two large-scale studies of dutasteride are currently investigating the role of near-maximal DHT suppression in the settings of prostate cancer risk reduction and expectant management of localized prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据